Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

Completed · Phase 2

Conditions studied: Aging, Skin Abnormalities

In brief

With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.

Key facts

Study ID

NCT00520910

Run by

University of Miami

People needed

10

Starts

2007-08-01

Expected to finish

2009-05-01

Last updated by the study team

2019-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects,
• 18 years of age or older,
• with Fitzpatrick skin types II and III.

You may not qualify if…

• Pregnancy
• Personal history of skin cancer
• History of abnormal photosensitivity
• Smokers
• Patients with history or being exposed to other forms of radiation (other than sunlight)
• History or current exposure to asbestos
• Patients taking any drug that might alter the response of skin to UVR (including, but are not limited to, doxycycline, sulfas, psoralens, and amiodarone)
• Patients unable to undergo skin biopsies
• History of abnormal scarring
• History of adverse reaction to local anesthesia

Where it is running

• University of Miami Skin Research Group Office — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.